11:12 AM EST, 12/11/2024 (MT Newswires) -- AstraZeneca ( AZN ) and Merck & Co. ( MRK ) said Wednesday that updated results from a phase 3 trial of Lynparza showed that the drug demonstrated a prolonged survival benefit in early breast cancer patients.

Data showed that Lynparza provided "clinically meaningful" improvements in overall survival, invasive disease-free survival, and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, the companies said.

The companies added that 87.5% of patients treated with Lynparza were alive at six years compared with 83.2% in the placebo group. The drug's safety and tolerability profile in the study was consistent with prior clinical trials and no new safety signals were identified during the longer follow-up.

Lynparza is being jointly developed and commercialized by AstraZeneca ( AZN ) and Merck & Co. ( MRK )

Price: 67.55, Change: +0.37, Percent Change: +0.55